801. Engineering extracellular vesicles for cancer therapy: recent advances and challenges in clinical translation.
- Author
-
Li S, Xu J, Qian J, and Gao X
- Subjects
- Drug Delivery Systems, Proteins, Extracellular Vesicles, MicroRNAs therapeutic use, Neoplasms drug therapy
- Abstract
Extracellular vesicles (EVs) are receiving increasing attention in recent years in the field of cancer treatment. EVs contain specific contents closely related to their donor cells, such as miRNAs, proteins and dsDNAs. As endogenous vesicles, EVs naturally have the characteristics of low toxicity and low immunogenicity and can stably pass through the circulatory system to reach the recipient cells, which make them good carriers to deliver therapeutic agents such as nucleic acid sequences and chemotherapeutics. In many preclinical studies and clinical trials, EVs have demonstrated their unlimited advantages in the field of cancer therapy. However, there are still some challenges that restrict their clinical application, such as yield, heterogeneity, safety, and specificity. In this review, we will focus on the latest breakthrough of EVs in the field of cancer treatment and discuss the challenges in the clinical translation of EVs.
- Published
- 2020
- Full Text
- View/download PDF